STOCK TITAN

Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences acquisition
Rhea-AI Summary
Pulse Biosciences to present at Gilmartin Group Emerging Growth Showcase on Sept 21, 2023.
Positive
  • None.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023 at 10:30am PT.

A live and archived webcast of the presentation will be available following the event on the “Investors” section of the company’s website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

Pulse Biosciences, Inc.

NASDAQ:PLSE

PLSE Rankings

PLSE Latest News

PLSE Stock Data

431.31M
16.31M
70.38%
8.07%
4.76%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
HAYWARD

About PLSE

pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and